Business
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury
First patient successfully completes dosing at Toronto General Hospital St. Michael’s ...
About this update from Arch Biopartners, Inc.
[{"type":"text","content":"Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury\n\n\n\n\n First patient successfully completes dosing at Toronto General Hospital\n \n\n St. Michael’s Hospital is expected to be the next Canadian clinical site activated\n \n\n Arch is looking for additional clinical sites in North America to join the trial\n \n\n\n TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) --\n \n Arch Biopartners Inc.\n \n (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the first patient has successfully completed dosing at Toronto General Hospital (TGH), part of the\n \n University Health Network (UHN)\n \n , Canada’s largest academic health sciences centre and a global leader in cardiac care and research. The volunteer patient completed five days of dosing as part of the Company’s ongoing Phase II trial evaluating LSALT peptide to prevent and treat cardiac surgery-associated acute kidney injury (CS-AKI).\n \n\n Toronto General Hospital, ranked as the #3 hospital in the world and Canada’s top-ranked hospital by\n \n\n Newsweek\n \n in its 2025 list of the World’s Best Hospitals\n \n , is the first clinical site in Ontario to dose a patient in this trial. TGH joins the University of Calgary Hospital as the second Canadian clinical site to dose patients in this trial.\n \n\n The Company anticipates St. Michael’s Hospital (SMH) in Toronto will be the next Canadian site to activate and enroll patients into the study, pending approvals from Clinical Trials Ontario and SMH’s ethics board.\n \n\n The Arch team continues to pursue additional clinical sites in Canada and the United States. Patient recruitment in Turkey is being limited to diversify the demographic and geographic patient data produced by the trial.\n \n\n Quote from Richard Muruve, CEO, Arch Biopartners:\n \n\n\n “The start of dosing at Toronto General Hospital marks an important milestone in advancing Arch’s Phase II CS-AKI trial. The goal is to recruit about half of the trial’s patients in North America. Patient dosing completed in Turkey has provided a strong safety profile for LSALT peptide. This has given clinical trial teams increased con...